
Screen-guided care reduced NICU admissions from 16.4% to 12.8% in a nulliparous PRIME trial subgroup
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
In a secondary analysis of 1,783 nulliparous participants from the 19-center PRIME randomized trial, a biomarker screen-guided, multicomponent care pathway reduced NICU admissions from 16.4% with routine care to 12.8%.
What NurseJet pulled from the source
The PRIME trial randomized 5,018 otherwise low-risk singleton pregnancies to routine care or a screen-guided strategy using the IGFBP4/SHBG biomarker ratio. This secondary analysis focused on 1,783 nulliparous participants, whose lack of prior obstetric history can make preterm-birth risk harder to identify. Participants in the screen-guided arm who screened as higher risk were offered vaginal progesterone, low-dose aspirin, and weekly telephone nursing support. Composite neonatal morbidity was lower with screen-guided care, and NICU admission occurred in 12.8% of the screen-guided group versus 16.4% with routine care (P=0.039), an adjusted OR of 0.75 (95% CI 0.57 to 0.98). The authors calculated that 28 nulliparous pregnancies would need screening to prevent one NICU admission; reductions were concentrated in spontaneous preterm births. No serious adverse events were reported in the screen-guided subgroup. Because this was a subgroup analysis of a multicomponent pathway, the effect cannot be assigned to screening, medication, or nursing follow-up alone.
Why this matters for nurses
First-time pregnancies lack a prior obstetric history to help identify preterm-birth risk, while obstetric nurses coordinate monitoring, education, and follow-up across pregnancy. This study matters because it tests a risk-guided pathway in that specific population and reports a neonatal outcome rather than screening performance alone.
Bedside takeaway
Worth knowing that a multicomponent, biomarker screen-guided pathway reduced NICU admission from 16.4% to 12.8% in a nulliparous PRIME subgroup, but the effect cannot be assigned to any one component.
Explain this for my unit
Key takeaways
- The secondary analysis included 1,783 nulliparous participants from a 5,018-participant, 19-center randomized trial.
- Higher-risk participants in the screen-guided arm were offered progesterone, low-dose aspirin, and weekly telephone nursing support.
- NICU admission was 12.8% with screen-guided care versus 16.4% with routine care (adjusted OR 0.75, 95% CI 0.57 to 0.98).
- The multicomponent pathway and subgroup design prevent attributing the result to any single component.
Practice implications
- For labor-and-delivery and prenatal teams, the findings support awareness of locally approved risk-screening pathways and reliable follow-up when a patient screens higher risk. They do not justify adopting this biomarker or changing aspirin or progesterone use outside institutional protocols and prescriber-directed care.
Limitations & cautions
- This was a secondary subgroup analysis rather than the trial's full primary analysis. The screen-guided arm combined a biomarker test, progesterone, aspirin, and nursing calls, so the contribution of each component is unknown; findings apply to otherwise low-risk singleton nulliparous pregnancies and may not extend to other populations.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
The Journal of Maternal-Fetal & Neonatal Medicine (PubMed)
The Journal of Maternal-Fetal & Neonatal Medicine (PubMed). Biomarker screen-guided care for preterm birth risk in nulliparous pregnancies: a subgroup analysis of the PRIME randomized controlled trial.
https://pubmed.ncbi.nlm.nih.gov/42420160/
Professional education only


